Gallium-68 Market Forecast to 2030 | Size, Share, Growth
Aperçu du marché et point de vue des analystes :
Le gallium-68 est un radio-isotope émetteur de positrons utilisé dans les procédures de diagnostic médical. Il est produit à partir d'un générateur de germanium-68/gallium-68 (68Ge/68Ga) et a une demi-vie de 68 minutes. Une augmentation de la prévalence du cancer de la prostate et des tumeurs neuroendocrines, ainsi qu’une recrudescence de l’utilisation des techniques d’imagerie nucléaire sont parmi les principaux facteurs propulsant la croissance du marché du gallium-68. Cependant, la courte durée de conservation du gallium-68 entrave la croissance du marché. En outre, l'utilisation de traceurs radioactifs dans le diagnostic du cancer devrait entraîner de nouvelles tendances sur le marché du gallium-68 dans les années à venir.
Moteurs de croissance :
Augmentation de la prévalence du cancer de la prostate et des tumeurs neuroendocrines Croissance du marché du gallium-68
La forte prévalence du cancer de la prostate et des tumeurs neuroendocrines entraîne une demande élevée de procédures de diagnostic par tomographie par émission de positons (TEP). Selon la Fondation Mayo pour l'éducation et la recherche médicales (MFMER), les tumeurs neuroendocrines se développent à partir d'une croissance maligne de cellules neuroendocrines. Le gallium-68 (Ga-68) est utilisé pour le radiomarquage d'agents de diagnostic radioactifs afin de localiser les tumeurs neuroendocrines positives pour les récepteurs de la somatostatine chez les adultes et les enfants via TEP. Selon Cancer Research UK, plus de 4 000 personnes reçoivent chaque année un diagnostic de tumeur neuroendocrine au Royaume-Uni. Environ 50 % des tumeurs neuroendocrines débutent dans le système digestif (estomac, intestin grêle et gros, pancréas et rectum) et environ 20 % débutent dans les poumons. Selon l'American Society of Clinical Oncology (ASCO), près de 12 000 personnes aux États-Unis reçoivent chaque année un diagnostic de tumeur neuroendocrine, et environ 171 000 personnes vivent avec ce diagnostic.
Le Ga-68 est principalement utilisé pour détecter les cellules cancéreuses dans le corps humain. Par exemple, l’agent d’imagerie TEP Ga-68 PSMA-11 est largement utilisé pour détecter les cellules cancéreuses de la prostate. Selon le Fonds mondial de recherche sur le cancer (WCRF) International, plus de 1,4 million de nouveaux cas de cancer de la prostate ont été signalés en 2020. De même, selon le Centre international de recherche sur le cancer (CIRC), le nombre de cas de cancer de la prostate est estimé à passer de ~1,47 million en 2022 à ~1,83 million d'ici 2030 et ~2,88 millions d'ici 2050. Ainsi, le cancer de la prostate et les tumeurs neuroendocrines nécessitent un diagnostic médical précis avec la TEP à base de Ga-68, ce qui contribue à améliorer la détection des tumeurs et facilite un traitement efficace planification. Par conséquent, la prévalence croissante de ces conditions renforce la taille du marché du gallium-68.
Segmentation et portée du rapport :
L'analyse du marché du gallium-68 a été réalisée en considérant les segments suivants : application et utilisateur final. Par application, le marché est segmenté en oncologie, neurologie, cardiologie et autres. Le segment de l’oncologie détenait la plus grande part de marché du gallium-68 en 2022 et devrait enregistrer le TCAC le plus élevé au cours de la période de prévision. Le marché du segment de l'oncologie est sous-segmenté en cancer de la prostate, tumeurs neuroendocrines et autres.
Le marché, par utilisateur final, est classé en hôpitaux, centres de diagnostic et d'imagerie, etc. Le segment des hôpitaux détenait la plus grande part de marché du gallium-68 en 2022. De plus, le même segment devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Analyse régionale :
La portée géographique de le rapport sur le marché du gallium-68 couvre l’Amérique du Nord, l’Europe, l’Asie-Pacifique, l’Amérique du Sud et centrale, ainsi que le Moyen-Orient et l’Afrique. En 2022, l’Amérique du Nord détenait la plus grande part de marché. Les progrès technologiques tels que l’imagerie hybride, l’introduction de nouveaux produits radiopharmaceutiques pour le diagnostic et le traitement et le développement de techniques d’imagerie moléculaire basées sur le principe du traceur contribuent de manière significative aux progrès de la médecine nucléaire aux États-Unis. L’accès à des infrastructures de soins de santé avancées, l’incidence et la prévalence croissantes du cancer de la prostate ainsi que les innovations de produits par des acteurs clés contribuent également à l’expansion du marché du gallium-68 en Amérique du Nord. Selon le Centre international de recherche sur le cancer (CIRC), le nombre de patients atteints de cancer aux États-Unis devrait passer de 2,28 millions de cas en 2020 à 3,12 millions de cas d'ici 2040. Ainsi, l'augmentation des cas de cancer devrait stimuler la demande en énergie nucléaire. l'imagerie, qui favorise la progression du marché du gallium-68.
Marché du gallium-68, par application – 2022 et 2030
Développements de l'industrie et opportunités futures :
Quelques développements stratégiques (selon les communiqués de presse de l'entreprise) des principaux acteurs opérant sur le marché du gallium-68 sont répertoriés ci-dessous :
•En décembre 2023, Ariceum Therapeutics a obtenu des brevets américains et canadiens pour son Gallium-68 (Ga- 68) kit de production radiopharmaceutique. La propriété intellectuelle a été développée par Theragnostics Ltd, qui a été acquise par Ariceum en 2023. Auparavant, la production de produits radiopharmaceutiques Ga-68 impliquait une approche en plusieurs étapes, qui limitait le nombre de doses aux patients pouvant être produites à tout moment. La plate-forme technologique Ga-68 de Theragnostics permet la production de doses multiples de Ga-68 HBED-PSMA-11 dans un seul flacon en une seule étape simple. En mars 2023, Telix Pharmaceuticals a reçu l'approbation de la FDA pour sa demande supplémentaire de nouveau médicament. (sNDA) pour Illuccix (kit de préparation pour injection de gozétotide Ga-68) pour le dépistage des patients atteints d'un cancer de la prostate métastatique, à qui on a recommandé un traitement dirigé par le Lutétium-177 PSMA.•En octobre 2022, Telix a obtenu l'approbation de Santé Canada pour Illuccix ( Kit de préparation pour injection de gozétotide Ga-68) destiné à être utilisé dans la stadification et la re-stadification du cancer de la prostate à risque intermédiaire et élevé, ainsi que pour la localisation du tissu tumoral dans le cancer de la prostate récurrent. Il est recommandé d'utiliser Illuccix, après radiomarquage au Ga-68, avec la TEP pour détecter les lésions PSMA-positives chez les hommes atteints d'un cancer de la prostate. En septembre 2021, Eckert & Ziegler Radiopharma GmbH a soumis un amendement à son Drug Master File (DMF) pour GalliaPharm à la FDA américaine, étendant ainsi son portefeuille de générateurs de Gallium-68 sur le marché américain. La société prévoyait de proposer son générateur breveté Ge-68/Ga-68 dans une taille allant jusqu'à 100 mCi, avec une durée de conservation de 12 mois ou 700 élutions. Le Ga-68 de GalliaPharm est utilisé pour préparer des médicaments d'imagerie diagnostique pour la TEP. Paysage concurrentiel et entreprises clés :
Novartis AG, Telix Pharmaceuticals (US) Inc, IRE-ELiT SA, ITM Medical Isotopes GmbH, Eckert & Ziegler Radiopharma GmbH, ARTMS Inc, IBA Radiopharma Solutions, Cardinal Health, Rosatom et Evergreen Theragnostics Inc font partie des principales sociétés présentées dans le rapport sur le marché du gallium-68. Ces entreprises se concentrent sur le développement de nouvelles technologies, la mise à niveau des produits existants et l'expansion de leur présence géographique pour répondre à la demande croissante des consommateurs du monde entier.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market, by end user, is categorized into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest gallium-68 market share in 2022 and it is anticipated to register the highest CAGR during the forecast period.
The gallium-68 market is expected to be valued at US$ 1.070.34 million in 2030.
By application, the market is segmented into oncology, neurology, cardiology, and others. The oncology segment held the largest gallium-68 market share in 2022 and it is anticipated to register the highest CAGR during the forecast period. Based on oncology the market is subsegmented into prostate cancer, neuroendocrine tumors, and others.
The gallium-68 market was valued at US$ 782.36 million in 2022.
The gallium-68 market majorly consists of the players, including Novartis AG, Telix Pharmaceuticals (US) Inc, IRE-ELiT SA, ITM Medical Isotopes GmbH, Eckert & Ziegler Radiopharma GmbH, ARTMS Inc, IBA Radiopharma Solutions, Cardinal Health, Rosatom, and Evergreen Theragnostics Inc.
Gallium-68 is a positron-emitting radioisotope used in medical diagnostic procedures produced from germanium-68/gallium-68 (68Ge/68Ga) generator. Gallium-68 has good positron-emitting properties and a half-life of 68 min.
Factors such as increase in the prevalence of prostate cancer and neuroendocrine tumors and the increasing use of nuclear imaging techniques propel the gallium-68 market growth.
The List of Companies - Gallium-68 Market
- Novartis AG
- Telix Pharmaceuticals (US) Inc
- IRE-ELiT SA
- ITM Medical Isotopes GmbH
- Eckert & Ziegler Radiopharma GmbH
- ARTMS Inc
- IBA Radiopharma Solutions
- Cardinal Health
- Rosatom
- Evergreen Theragnostics Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2024
Bioreactors Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Scale (Lab-Scale Production, Pilot-Scale Production, and Full-Scale Production), Application (Microbial Application, Cell Culture Application, and Others), Technology (Fed-Batch Bioreactors and Perfusion Bioreactors), End User (Biopharma Manufacturers, Research and Development Organizations, and Contract Manufacturing Organization), and Geography
Mar 2024
Poultry Diagnostics Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Test Type [Enzyme-Linked Immunosorbent Assay (ELISA) Tests, Polymerase Chain Reaction (PCR) Test, Hemagglutination-Inhibition (HI), and Others], Disease (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Mycoplasmosis, Infectious Bronchitis, and Others), and Geography
Mar 2024
ELISA Diagnostics Tests Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography
Mar 2024
Direct-To-Consumer Genetic Testing Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Test Type (Nutrigenomics Testing, Predictive Testing, Carrier Testing, and Others), Technology (Whole Genome Sequencing, Single Nucleotide Polymorphism Chips, Targeted Analysis, and Others), Distribution Channel (Online and Offline), and Geography
Mar 2024
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Mar 2024
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Mar 2024
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Get Free Sample For